Ubrelvy (Ubrogepant) During Breastfeeding
Ubrelvy is safe to use while breastfeeding, as only minimal amounts transfer into breast milk with no clinically relevant infant exposure.
FDA-Approved Safety Data
The FDA label for Ubrelvy provides definitive lactation data from a dedicated study in breastfeeding women 1:
- Relative infant dose: 0.15% of the maternal weight-adjusted dose—well below the 10% threshold generally considered safe 1
- Milk-to-plasma ratio: 0.23, indicating low transfer into breast milk 1
- Cumulative excretion: <0.02 mg of a 100 mg dose enters breast milk over 24 hours 1
- By 16-24 hours post-dose, only 17% of women had detectable ubrogepant levels in breast milk 1
Clinical Study Confirmation
A 2025 pharmacokinetic study in 12 healthy lactating women confirmed these findings 2:
- Mean milk-to-plasma ratio of 0.23 2
- Maximum breast milk concentration and AUC were 75% and 78% lower than plasma levels, respectively 2
- The minimal transfer was deemed "not clinically relevant" 2
- Only two mild adverse events occurred across all participants 2
Practical Recommendations
You can prescribe Ubrelvy to breastfeeding women without requiring any special precautions:
- No need to "pump and dump" breast milk 1
- No required waiting period between dosing and breastfeeding 1
- Standard dosing applies: 50-100 mg as needed for migraine, with option for second dose after 2 hours if needed (maximum 200 mg/24 hours) 1
Clinical Context
The FDA label explicitly states: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for UBRELVY" 1. Given the extremely low infant exposure (0.15% relative infant dose), the benefits of treating maternal migraine clearly outweigh any theoretical risk to the infant 1, 2.
This recommendation is based on actual human lactation data, not extrapolation from animal studies or theoretical concerns—making it one of the better-studied acute migraine medications for breastfeeding safety 1, 2.